

Charlotte Kloft

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2081243/publications.pdf>

Version: 2024-02-01

102
papers

1,861
citations

304368

22
h-index

329751

37
g-index

105
all docs

105
docs citations

105
times ranked

2264
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes. Canadian Respiratory Journal, 2018, 2018, 1-11.	0.8	174
2	Therapeutic drug monitoring of oral targeted antineoplastic drugs. European Journal of Clinical Pharmacology, 2021, 77, 441-464.	0.8	110
3	Population Pharmacokinetic-Pharmacodynamic Model for Neutropenia with Patient Subgroup Identification: Comparison across Anticancer Drugs. Clinical Cancer Research, 2006, 12, 5481-5490.	3.2	78
4	Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs. AAPS Journal, 2015, 17, 853-870.	2.2	68
5	Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model. Journal of Antimicrobial Chemotherapy, 2018, 73, 1330-1339.	1.3	63
6	TDMx: A novel web-based open-access support tool for optimising antimicrobial dosing regimens in clinical routine. International Journal of Antimicrobial Agents, 2015, 45, 442-444.	1.1	59
7	Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study. Critical Care, 2017, 21, 263.	2.5	52
8	Separation and identification of platinum adducts with DNA nucleotides by capillary zone electrophoresis and capillary zone electrophoresis coupled to mass spectrometry. Electrophoresis, 2001, 22, 97-103.	1.3	51
9	Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis. International Journal of Antimicrobial Agents, 2019, 54, 309-317.	1.1	48
10	Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients. Clinical Pharmacokinetics, 2017, 56, 617-633.	1.6	47
11	Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism. Drug Metabolism Reviews, 2019, 51, 247-265.	1.5	41
12	Pharmacodynamic and response surface analysis of linezolid or vancomycin combined with meropenem against Staphylococcus aureus. Pharmaceutical Research, 2015, 32, 2410-2418.	1.7	37
13	Quality of compounded hydrocortisone capsules used in the treatment of children. European Journal of Endocrinology, 2017, 177, 239-242.	1.9	37
14	Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients. Journal of Clinical Pharmacology, 2016, 56, 307-315.	1.0	35
15	Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations. Clinical Pharmacology and Therapeutics, 2021, 109, 29-36.	2.3	35
16	Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships of Monoclonal Antibodies in Children. Clinical Pharmacokinetics, 2015, 54, 35-80.	1.6	34
17	Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach. British Journal of Clinical Pharmacology, 2016, 81, 538-552.	1.1	30
18	Simultaneous determination and stability studies of linezolid, meropenem and vancomycin in bacterial growth medium by high-performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1028, 242-248.	1.2	29

#	ARTICLE	IF	CITATIONS
19	Evolution of a mini-scale biphasic dissolution model: Impact of model parameters on partitioning of dissolved API and modelling of in vivo-relevant kinetics. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 105, 166-175.	2.0	29
20	Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 347-358.	1.3	27
21	Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration. <i>AAPS Journal</i> , 2017, 19, 223-233.	2.2	25
22	In search of a standard when analyzing medication adherence in patients with heart failure using claims data: a systematic review. <i>Heart Failure Reviews</i> , 2018, 23, 63-71.	1.7	25
23	Utilising the EGFR interactome to identify mechanisms of drug resistance in non-small cell lung cancer – Proof of concept towards a systems pharmacology approach. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 94, 20-32.	1.9	22
24	Systems pharmacology in drug development and therapeutic use – A forthcoming paradigm shift. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 94, 1-3.	1.9	21
25	Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2018, 57, 229-242.	1.6	21
26	Bayesian Data Assimilation to Support Informed Decision Making in Individualized Chemotherapy. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 153-164.	1.3	21
27	Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. <i>Cancers</i> , 2021, 13, 2782.	1.7	21
28	Unbound fraction of ertapenem in intensive care unit patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3108-3111.	1.3	20
29	Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 48, 134-140.	1.1	19
30	Evaluating patients' comprehensibility of a standardized medication plan. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1229-1237.	0.8	19
31	Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen. <i>Frontiers in Pharmacology</i> , 2020, 11, 283.	1.6	19
32	Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e1729-e1740.	1.8	18
33	In vitro microdialysis recovery and delivery investigation of cytokines as prerequisite for potential biomarker profiling. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 57, 48-59.	1.9	17
34	Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-Small Cell Lung Cancer Receiving Erlotinib Treatment. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 309-315.	1.2	17
35	Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 661-670.	2.3	17
36	Reinforcement learning and Bayesian data assimilation for model-informed precision dosing in oncology. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 241-254.	1.3	17

#	ARTICLE	IF	CITATIONS
37	Pilot Investigation on Long-Term Subcutaneous Microdialysis: Proof of Principle in Humans. <i>AAPS Journal</i> , 2013, 15, 95-103.	2.2	16
38	Patients’ handling of a standardized medication plan: a pilot study and method development. <i>Patient Preference and Adherence</i> , 2016, 10, 621.	0.8	16
39	Predicting Cortisol Exposure from Paediatric Hydrocortisone Formulation Using a Semi-Mechanistic Pharmacokinetic Model Established in Healthy Adults. <i>Clinical Pharmacokinetics</i> , 2018, 57, 515-527.	1.6	15
40	Plasma and tissue pharmacokinetics of fosfomycin in morbidly obese and non-obese surgical patients: a controlled clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2335-2340.	1.3	15
41	Toxicity of High-Dose Carboplatin: Ultrafiltered and Not Total Plasma Pharmacokinetics Is of Clinical Relevance. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 762-773.	1.0	14
42	Modelébased evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 739-753.	1.1	14
43	Drug combinations and impact of experimental conditions on relative recovery in in vitro microdialysis investigations. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 127, 252-260.	1.9	14
44	Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2021, 9, 91-101.	1.6	14
45	Meropenem Plasma and Interstitial Soft Tissue Concentrations in Obese and Nonobese Patients’ A Controlled Clinical Trial. <i>Antibiotics</i> , 2020, 9, 931.	1.5	14
46	Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1609-1613.	0.8	13
47	Linezolid Concentrations in Plasma and Subcutaneous Tissue are Reduced in Obese Patients, Resulting in a Higher Risk of Underdosing in Critically Ill Patients: A Controlled Clinical Pharmacokinetic Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1067.	1.0	13
48	Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study. <i>Annals of Intensive Care</i> , 2020, 10, 48.	2.2	13
49	Pharmacokinetics of the Inhaled Selective Glucocorticoid Receptor Modulator AZD5423 Following Inhalation Using Different Devices. <i>AAPS Journal</i> , 2017, 19, 865-874.	2.2	12
50	High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 131, 218-229.	1.9	12
51	Quantification of microdialysis related variability in humans: Clinical trial design recommendations. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 157, 105607.	1.9	12
52	Population pharmacokinetics meets microdialysis: Benefits, pitfalls and necessities of new analysis approaches for human microdialysis data. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 57, 68-73.	1.9	11
53	Concentration"response studies and modelling of the pharmacodynamics of linezolid: <i>Staphylococcus aureus</i> versus <i>Enterococcus faecium</i> . <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 54-60.	1.1	11
54	No clinically relevant removal of meropenem by cytokine adsorber CytoSorb® in critically ill patients with sepsis or septic shock. <i>Intensive Care Medicine</i> , 2021, 47, 1332-1333.	3.9	11

#	ARTICLE	IF	CITATIONS
55	Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2114-2120.	1.3	10
56	Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young children. <i>European Journal of Endocrinology</i> , 2020, 183, 357-368.	1.9	10
57	The circadian rhythm of corticosteroid-binding globulin has little impact on cortisol exposure after hydrocortisone dosing. <i>Clinical Endocrinology</i> , 2019, 91, 33-40.	1.2	9
58	A rapid, simple and sensitive liquid chromatography tandem mass spectrometry assay to determine amoxicillin concentrations in biological matrix of little volume. <i>Talanta</i> , 2019, 201, 253-258.	2.9	9
59	Rationale of a lower dexamethasone dose in prenatal congenital adrenal hyperplasia therapy based on pharmacokinetic modelling. <i>European Journal of Endocrinology</i> , 2021, 185, 365-374.	1.9	8
60	A continued learning approach for model-informed precision dosing: Updating models in clinical practice. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 185-198.	1.3	8
61	Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. <i>Cancers</i> , 2021, 13, 6281.	1.7	8
62	Role of TDM-based dose adjustments for taxane anticancer drugs. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 306-316.	1.1	7
63	Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line. <i>Cells</i> , 2021, 10, 716.	1.8	7
64	Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Reponse Exemplified by Levofloxacin. <i>Pharmaceutical Research</i> , 2021, 38, 381-395.	1.7	7
65	Population Pharmacokinetic Analysis of a Nevirapine-Based HIV-1 Prevention of Mother-to-Child Transmission Program in Uganda to Assess the Impact of Different Dosing Regimens for Newborns. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 294-304.	1.0	6
66	Semimechanistic Clearance Models of Oncology Biotherapeutics and Impact of Study Design: Cetuximab as a Case Study. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 628-638.	1.3	6
67	Quantitative relationship between infliximab exposure and inhibition of C-reactive protein synthesis to support inflammatory bowel disease management. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2374-2384.	1.1	6
68	Decoding (patho-)physiology of the lung by advanced in vitro models for developing novel anti-infectives therapies. <i>Drug Discovery Today</i> , 2021, 26, 148-163.	3.2	6
69	Quantification of persister formation of <i>Escherichia coli</i> leveraging electronic cell counting and semi-mechanistic pharmacokinetic/pharmacodynamic modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2088-2096.	1.3	6
70	Target Site Pharmacokinetics of Meropenem: Measurement in Human Explanted Lung Tissue by Bronchoalveolar Lavage, Microdialysis, and Homogenized Lung Tissue. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0156421.	1.4	6
71	Microdialysis sampling to monitor target-site vancomycin concentrations in septic infants: a feasible way to close the knowledge gap. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106405.	1.1	6
72	Evaluating prediction methods for glomerular filtration to optimise drug doses in obese and nonobese patients. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2973-2981.	1.1	6

#	ARTICLE	IF	CITATIONS
73	Impact of altered endogenous IgG on unspecific mAb clearance. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 351-374.	0.8	5
74	Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non-Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 430-438.	1.3	5
75	Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients. <i>Antibiotics</i> , 2021, 10, 468.	1.5	5
76	Understanding and reducing complex systems pharmacology models based on a novel input-response index. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018, 45, 139-157.	0.8	4
77	Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1405-1414.	1.0	4
78	Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 235-242.	1.0	4
79	Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies. <i>Pharmaceutics</i> , 2021, 14, 115.	1.7	4
80	Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure-Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant <i>Escherichia coli</i> . <i>Antibiotics</i> , 2021, 10, 615.	1.5	4
81	Similar Piperacillin/Tazobactam Target Attainment in Obese versus Nonobese Patients despite Differences in Interstitial Tissue Fluid Pharmacokinetics. <i>Pharmaceutics</i> , 2021, 13, 1380.	2.0	4
82	A versatile high-performance LC-MS/MS assay for the quantification of voriconazole and its N-oxide metabolite in small sample volumes of multiple human matrices for biomedical applications. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 210, 114551.	1.4	4
83	Combination of Pharmacokinetic and Pathogen Susceptibility Information To Optimize Meropenem Treatment of Gram-Negative Infections in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0183121.	1.4	4
84	Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism. <i>Pharmaceutics</i> , 2022, 14, 477.	2.0	4
85	Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients. <i>Clinical Pharmacokinetics</i> , 2022, 61, 655-672.	1.6	4
86	Adherence to tamoxifen in breast cancer patients: What role does the pharmacist play in German primary care?. <i>Canadian Pharmacists Journal</i> , 2019, 152, 28-34.	0.4	3
87	EGb 761 [®] Does Not Affect Blood Coagulation and Bleeding Time in Patients with Probable Alzheimer's Disease: Secondary Analysis of a Randomized, Double-Blind Placebo-Controlled Trial. <i>Healthcare (Switzerland)</i> , 2021, 9, 1678.	1.0	3
88	Development of a Model-Informed Dosing Tool to Optimise Initial Antibiotic Dosing: A Translational Example for Intensive Care Units. <i>Pharmaceutics</i> , 2021, 13, 2128.	2.0	3
89	Novel non-substrate modulators of the transmembrane efflux pump P-glycoprotein (ABCB1). <i>MedChemComm</i> , 2015, 6, 860-866.	3.5	2
90	A Model-Based Pharmacokinetic/Pharmacodynamic Analysis of the Combination of Amoxicillin and Monophosphoryl Lipid A Against <i>S. pneumoniae</i> in Mice. <i>Pharmaceutics</i> , 2021, 13, 469.	2.0	2

#	ARTICLE	IF	CITATIONS
91	CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications. <i>Archives of Toxicology</i> , 2021, 95, 2867-2870.	1.9	2
92	The Biosynthetic Monophosphoryl Lipid A Enhances the Therapeutic Outcome of Antibiotic Therapy in Pneumococcal Pneumonia. <i>ACS Infectious Diseases</i> , 2021, 7, 2164-2175.	1.8	2
93	Exploring Dried Blood Spot Cortisol Concentrations as an Alternative for Monitoring Pediatric Adrenal Insufficiency Patients: A Model-Based Analysis. <i>Frontiers in Pharmacology</i> , 2022, 13, 819590.	1.6	2
94	Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools. <i>Antibiotics</i> , 2022, 11, 758.	1.5	2
95	Cytokine and Chemokine Recovery Is Increased by Colloid Perfusates during Dermal Microdialysis. <i>Materials</i> , 2018, 11, 682.	1.3	1
96	Comment on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. <i>Pharmaceutical Statistics</i> 17 (5):593-606, Sep/Oct 2018, DOI: 10.1002/pst.1873. <i>Pharmaceutical Statistics</i> , 2019, 18, 278-281.	0.7	1
97	What Impact Do NLME Publications Have Outside Our Community?. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 191-194.	1.3	1
98	The Use of Translational Modelling and Simulation to Develop Immunomodulatory Therapy as an Adjunct to Antibiotic Treatment in the Context of Pneumonia. <i>Pharmaceutics</i> , 2021, 13, 601.	2.0	1
99	Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups. <i>Cancers</i> , 2021, 13, 2432.	1.7	1
100	Cost-effectiveness of oral anticancer drugs and associated individualised dosing approaches in patients with cancer: protocol for a systematic review. <i>BMJ Open</i> , 2021, 11, e047173.	0.8	1
101	Pharmacometrics and systems biology in oncology: Is there an intersection?. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 51, 89-90.	0.3	1
102	Response to Hydrocortisone suspension formulations are not necessarily the same in the treatment of children with congenital adrenal hyperplasia™. <i>European Journal of Endocrinology</i> , 2020, 183, L29-L30.	1.9	0